Katanosin B and plusbacin A3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus

被引:85
作者
Maki, H [1 ]
Miura, K [1 ]
Yamano, Y [1 ]
机构
[1] Shionogi & Co Ltd, Discovery Res Labs, Toyonaka, Osaka 5610825, Japan
关键词
D O I
10.1128/AAC.45.6.1823-1827.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Both katanosin B and plusbacin A, are naturally occurring cyclic depsipeptide antibiotics containing a lactone linkage. They showed strong antibacterial activity against methicillin-resistant Staphylococcus aureus and VanA-type vancomycin-resistant enterococci, with MICs ranging from 0.39 to 3.13 mug/ml, as well as against other gram-positive bacteria. They inhibited the incorporation of N-acetylglucosamine, a precursor of cell wall synthesis, into peptidoglycan of S. aureus whole cells at concentrations close to their MICs, In vitro studies with a wall-membrane particulate fraction of S. aureus showed that katanosin E and plusbacin A, inhibited the formation of lipid intermediates, with 50% inhibitory concentrations (IC(50)s) of 2.2 and 2.3 mug/ml, respectively, and inhibited the formation of nascent peptidoglycan,,vith IC(50)s of 0.8 and 0.4 mug/ml, respectively. Vancomycin, a well-known inhibitor of transglycosylation, did not inhibit the formation of lipid intermediates but did inhibit the formation of nascent peptidoglycan, with an IC50 of 4.1 mug/ml. Acetyl-Lys-D-Ala-D-Ala, an analog of the terminus of the lipid intermediates, effectively suppressed the inhibition of transglycosylation by vancomycin, but did not suppress those by katanosin B and plusbacin A(3). These results indicate that the antibacterial activity of katanosin B and plusbacin A(3) is due to blocking of transglycosylation and its foregoing steps of cell wall peptidoglycan synthesis via a mechanism differing from that of vancomycin.
引用
收藏
页码:1823 / 1827
页数:5
相关论文
共 42 条
[1]   THE STRUCTURE AND MODE OF ACTION OF GLYCOPEPTIDE ANTIBIOTICS OF THE VANCOMYCIN GROUP [J].
BARNA, JCJ ;
WILLIAMS, DH .
ANNUAL REVIEW OF MICROBIOLOGY, 1984, 38 :339-357
[2]   LYSOBACTIN, A NOVEL ANTIBACTERIAL AGENT PRODUCED BY LYSOBACTER SP .2. BIOLOGICAL PROPERTIES [J].
BONNER, DP ;
OSULLIVAN, J ;
TANAKA, SK ;
CLARK, JM ;
WHITNEY, RR .
JOURNAL OF ANTIBIOTICS, 1988, 41 (12) :1745-1751
[3]   Topological analysis of the MraY protein catalysing the first membrane step of peptidoglycan synthesis [J].
Bouhss, A ;
Mengin-Lecreulx, D ;
Le Beller, D ;
van Heijenoort, J .
MOLECULAR MICROBIOLOGY, 1999, 34 (03) :576-585
[4]   Slow binding inhibition of phospho-N-acetylmuramyl-pentapeptide-translocase (Escherichia coli) by mureidomycin A [J].
Brandish, PE ;
Burnham, MK ;
Lonsdale, JT ;
Southgate, R ;
Inukai, M ;
Bugg, TDH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7609-7614
[5]   Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics [J].
Brötz, H ;
Josten, M ;
Wiedemann, I ;
Schneider, U ;
Götz, F ;
Bierbaum, G ;
Sahl, HG .
MOLECULAR MICROBIOLOGY, 1998, 30 (02) :317-327
[6]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P813
[7]   UDP-N-acetylglucosamine:: N-acetylmuramoyl-(pentapeptide) pyrophosphoryl undecaprenol N-acetylglucosamine transferase from Escherichia coli:: overproduction, solubilization, and purification [J].
Crouvoisier, M ;
Mengin-Lecreulx, D ;
van Heijenoort, J .
FEBS LETTERS, 1999, 449 (2-3) :289-292
[8]   The kinetic characterization of Escherichia coli MurG using synthetic substrate analogues [J].
Ha, S ;
Chang, E ;
Lo, MC ;
Men, H ;
Park, P ;
Ge, M ;
Walker, S .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1999, 121 (37) :8415-8426
[9]   Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50 [J].
Hanaki, H ;
Labischinski, H ;
Inaba, Y ;
Kondo, N ;
Murakami, H ;
Hiramatsu, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (03) :315-320
[10]   Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50 [J].
Hanaki, H ;
Kuwahara-Arai, K ;
Boyle-Vavra, S ;
Daum, RS ;
Labischinski, H ;
Hiramatsu, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :199-209